Login
$JSPR
$12.41 +$0.64 (5.44%) After hours

$JSPR SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
16 Nov 2026 10-Q
16 Nov 2026 8-K: Results of Operations and Financial Condition

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

13 Nov 2026 8-K: Other Events
13 Nov 2026 SCHEDULE 13G
09 Nov 2026 8-K: Other Events

REDWOOD CITY, Calif., November 9, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat...

04 Nov 2026 8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

REDWOOD CITY, Calif., November 4, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat...

28 Oct 2026 SCHEDULE 13G
23 Oct 2026 AMENDMENT NO. 1 TO FORM SC TO-I
19 Oct 2026 PROXY STATEMENT
15 Oct 2026 8-K: Other Events

Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy

14 Oct 2026 REGISTRATION STATEMENT
09 Oct 2026 PROXY STATEMENT
07 Oct 2026 8-K: Other Events

REDWOOD CITY, Calif., October 7, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat ...

07 Oct 2026 FORM SC TO-I
05 Oct 2026 8-K: Submission of Matters to a Vote of Security Holders

On September 30, 2026, Jasper Therapeutics, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, a total of 21,747,865 shares of the Company’s voting common stock, $0.0001 par value...

05 Oct 2026 8-K/A: Financial Statements and Exhibits

For the Six Months Ended June 30, 2026 and the Year Ended December 31, 2025

01 Oct 2026 8-K/A: Financial Statements and Exhibits

Consolidated Statements of Operations and Comprehensive Loss

28 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

On September 23, 2026, Herb Cross submitted his resignation, effective as of October 9, 2026, as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Jasper Therapeutics, Inc. (the...

24 Sep 2026 25-NSE

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support